Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 6 | 2018 | 493 | 1.190 |
Why?
|
| Adenocarcinoma | 5 | 2018 | 300 | 1.180 |
Why?
|
| Carrier Proteins | 3 | 2017 | 136 | 1.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 2 | 2016 | 2 | 1.010 |
Why?
|
| Colorectal Neoplasms | 3 | 2017 | 222 | 1.000 |
Why?
|
| Glioma | 2 | 2017 | 136 | 0.940 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 428 | 0.920 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 193 | 0.800 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 264 | 0.750 |
Why?
|
| Neoplasms | 3 | 2018 | 761 | 0.730 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 647 | 0.690 |
Why?
|
| MicroRNAs | 3 | 2018 | 188 | 0.660 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2017 | 18 | 0.630 |
Why?
|
| Endometrial Neoplasms | 2 | 2018 | 48 | 0.630 |
Why?
|
| Pancreatic Neoplasms | 2 | 2017 | 129 | 0.590 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 3 | 0.570 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2017 | 4 | 0.540 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 470 | 0.530 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 22 | 0.520 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 54 | 0.520 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 23 | 0.520 |
Why?
|
| Signal Transduction | 3 | 2017 | 686 | 0.520 |
Why?
|
| Chromosomal Instability | 1 | 2016 | 5 | 0.510 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 4 | 0.510 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 220 | 0.500 |
Why?
|
| Autophagy | 1 | 2017 | 55 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 157 | 0.500 |
Why?
|
| NF-kappa B | 1 | 2016 | 83 | 0.490 |
Why?
|
| Apoptosis | 1 | 2017 | 362 | 0.450 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 192 | 0.440 |
Why?
|
| Disease Progression | 4 | 2017 | 594 | 0.440 |
Why?
|
| Down-Regulation | 3 | 2018 | 134 | 0.380 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 726 | 0.380 |
Why?
|
| Humans | 22 | 2018 | 32798 | 0.380 |
Why?
|
| Female | 15 | 2018 | 20261 | 0.320 |
Why?
|
| Cell Movement | 4 | 2016 | 171 | 0.300 |
Why?
|
| Prognosis | 6 | 2018 | 1544 | 0.290 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2017 | 71 | 0.280 |
Why?
|
| Mice, Nude | 3 | 2017 | 290 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 59 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 135 | 0.260 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2016 | 27 | 0.250 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 145 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 835 | 0.240 |
Why?
|
| Animals | 6 | 2018 | 7569 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 456 | 0.210 |
Why?
|
| Mice | 4 | 2018 | 2511 | 0.210 |
Why?
|
| Male | 8 | 2018 | 19641 | 0.200 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 4032 | 0.190 |
Why?
|
| Genes, p53 | 2 | 2018 | 23 | 0.170 |
Why?
|
| Membrane Proteins | 2 | 2018 | 251 | 0.160 |
Why?
|
| Gene Deletion | 2 | 2018 | 65 | 0.160 |
Why?
|
| Middle Aged | 7 | 2018 | 12125 | 0.160 |
Why?
|
| Aged | 6 | 2018 | 10538 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 754 | 0.160 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 36 | 0.160 |
Why?
|
| Protein Binding | 2 | 2017 | 200 | 0.160 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 169 | 0.150 |
Why?
|
| Transfection | 2 | 2016 | 184 | 0.150 |
Why?
|
| CA-125 Antigen | 1 | 2018 | 6 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 24 | 0.140 |
Why?
|
| Germ Cells | 1 | 2018 | 10 | 0.140 |
Why?
|
| beta Catenin | 1 | 2018 | 36 | 0.140 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2017 | 5 | 0.140 |
Why?
|
| DNA Damage | 1 | 2018 | 93 | 0.140 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 39 | 0.140 |
Why?
|
| Transcription Factor RelA | 1 | 2017 | 22 | 0.140 |
Why?
|
| Oncogene Fusion | 1 | 2017 | 1 | 0.140 |
Why?
|
| NFATC Transcription Factors | 1 | 2017 | 5 | 0.140 |
Why?
|
| Vesicular Transport Proteins | 1 | 2017 | 10 | 0.140 |
Why?
|
| Immunoglobulins | 1 | 2017 | 13 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 12 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 35 | 0.130 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 15 | 0.130 |
Why?
|
| Adult | 4 | 2018 | 9560 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 36 | 0.130 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 14 | 0.130 |
Why?
|
| Clone Cells | 1 | 2017 | 35 | 0.130 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 17 | 0.130 |
Why?
|
| Genes, ras | 1 | 2017 | 25 | 0.130 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 23 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 113 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 78 | 0.130 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2016 | 12 | 0.130 |
Why?
|
| Pseudopodia | 1 | 2016 | 2 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2018 | 486 | 0.130 |
Why?
|
| Cytoskeleton | 1 | 2016 | 19 | 0.130 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2016 | 1 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 84 | 0.130 |
Why?
|
| p21-Activated Kinases | 1 | 2016 | 5 | 0.130 |
Why?
|
| Cell Shape | 1 | 2016 | 28 | 0.130 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 5 | 0.130 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 72 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 34 | 0.130 |
Why?
|
| Base Sequence | 1 | 2017 | 247 | 0.130 |
Why?
|
| Oncogenes | 1 | 2016 | 14 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 98 | 0.120 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 21 | 0.120 |
Why?
|
| Doxycycline | 1 | 2016 | 26 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 103 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2017 | 144 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 113 | 0.120 |
Why?
|
| Animals, Newborn | 1 | 2016 | 119 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 316 | 0.120 |
Why?
|
| Carcinoma | 1 | 2016 | 92 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 203 | 0.120 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 256 | 0.120 |
Why?
|
| Models, Biological | 1 | 2017 | 392 | 0.110 |
Why?
|
| Young Adult | 2 | 2018 | 2730 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2017 | 1282 | 0.100 |
Why?
|
| Smoking | 1 | 2017 | 531 | 0.100 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 1163 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1012 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2018 | 3701 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 599 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 326 | 0.090 |
Why?
|
| Child | 1 | 2017 | 2478 | 0.090 |
Why?
|
| African Americans | 1 | 2017 | 1424 | 0.080 |
Why?
|
| Adolescent | 1 | 2017 | 3638 | 0.080 |
Why?
|
| Sulfides | 2 | 2018 | 26 | 0.070 |
Why?
|
| Caprylates | 2 | 2018 | 27 | 0.070 |
Why?
|
| RNA Interference | 2 | 2017 | 77 | 0.060 |
Why?
|
| Genotype | 2 | 2018 | 731 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 764 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 1066 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 71 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 148 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 1 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 11 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 17 | 0.040 |
Why?
|
| Protein Transport | 1 | 2018 | 72 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 20 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2018 | 22 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2018 | 40 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2018 | 19 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 19 | 0.030 |
Why?
|
| Retreatment | 1 | 2018 | 40 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2018 | 51 | 0.030 |
Why?
|
| Cytarabine | 1 | 2018 | 55 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2017 | 7 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 10 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2017 | 11 | 0.030 |
Why?
|
| Acetylation | 1 | 2017 | 16 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 220 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2017 | 21 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 70 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 5 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 258 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2018 | 72 | 0.030 |
Why?
|
| CpG Islands | 1 | 2017 | 45 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2018 | 105 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 122 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 117 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2017 | 11 | 0.030 |
Why?
|
| Leucovorin | 1 | 2017 | 23 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2017 | 14 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 169 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 27 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 28 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2017 | 19 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 60 | 0.030 |
Why?
|
| Leukocytes | 1 | 2017 | 57 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 150 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 107 | 0.030 |
Why?
|
| Camptothecin | 1 | 2017 | 48 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 46 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 226 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2017 | 43 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 282 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 245 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 57 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 433 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2017 | 82 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2017 | 81 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 31 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 576 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 52 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 107 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 24 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 129 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 206 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 80 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 165 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 549 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 497 | 0.030 |
Why?
|
| Algorithms | 1 | 2018 | 511 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1844 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 602 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 2183 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 3438 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 3974 | 0.020 |
Why?
|